Hexarelin is a synthetic hexapeptide that produces the highest peak growth hormone levels of any GHRP studied in humans. But the GH release is only half the story. Hexarelin has a parallel mechanism — direct cardiac receptor binding through CD36 — that produces cardiovascular effects completely independent of growth hormone.
This dual-mechanism profile makes hexarelin unique among GH secretagogues. No other GHRP has human cardiac data showing acute improvements in left ventricular function during bypass surgery.
This article covers 6 research-backed effects, ranked by evidence quality. For an in-depth look at hexarelin's position in the GHRP hierarchy, see Hexarelin: The Strongest GHRP.
For dosing protocols, see the Hexarelin Dosing Guide.
Key Benefits at a Glance
| Benefit | Evidence Level | Key Finding |
|---|---|---|
| GH release | Human clinical trials | Highest peak GH of any GHRP |
| Cardiac function | Human + preclinical | Increased LVEF via CD36, GH-independent |
| Cardioprotection | Preclinical (extensive) | Ischemia-reperfusion protection, anti-fibrotic |
| Anti-atherosclerotic | Animal studies | Suppressed diet-induced atherosclerosis |
| Bone density | Animal studies | Increased bone mineral content in female rats |
| GHRH synergy | Human data | Supraphysiologic GH when combined |
1. Growth Hormone Release (Strongest Evidence — Highest of Any GHRP)
Evidence level: Multiple human clinical trials
Hexarelin produces the most potent GH release of any growth hormone releasing peptide. In head-to-head rat studies, hexarelin achieved peak plasma GH of 552 ng/ml versus 386 ng/ml for GHRP-6 at comparable doses (Dickson et al., 1995).
In humans, hexarelin at standard doses induces GH responses stronger than GHRH — and it is a powerful stimulus across age groups. In pubertal children and adults, hexarelin produced robust GH release, though the response was attenuated in prepubertal children and elderly subjects (Loche et al., 1998).
The GH response to hexarelin is dose-dependent. A dose-response study showed linear increases in GH, cortisol, and prolactin release across escalating doses (Ghigo et al., 1996).
Like other GHRPs, hexarelin also raises ACTH, cortisol, and prolactin — distinguishing it from the clean GH release of ipamorelin. In direct comparison, hexarelin and GHRP-2 produced similar strong GH responses at 1 mcg/kg IV, both exceeding GHRH (Arvat et al., 1997).
The key limitation: hexarelin shows more pronounced GH-response desensitization with chronic use than other GHRPs. GH output decreases by roughly 50% after 4 weeks of continuous twice-daily dosing (Rahim et al., 1999). This is reversible — GH response recovers to baseline within 4 weeks of discontinuation (Rahim et al., 2000).
2. Acute Cardiac Function Improvement (Human Evidence)
Evidence level: Human clinical studies
This is hexarelin's most distinctive benefit and what separates it from every other GHRP. Hexarelin directly improves cardiac function through a mechanism that does not require growth hormone.
In hypopituitary adults (who cannot produce GH), hexarelin increased left ventricular ejection fraction (LVEF) in both patients and controls without changing catecholamine levels, blood pressure, or cardiac output (Bisi et al., 1999). This proves the cardiac effect is GH-independent.
During coronary artery bypass surgery, acute hexarelin administration induced a prompt increase in LVEF, cardiac index, and cardiac output lasting up to 90 minutes (Broglio et al., 2002).
The mechanism involves a novel cardiac receptor identified as CD36, a multifunctional glycoprotein expressed in cardiomyocytes and microvascular endothelial cells (Bodart et al., 2002). This cardiac-specific binding site was initially identified through hexarelin research (Bhatt et al., 1999).
No other GHRP has human cardiac function data of this quality.
3. Ischemia-Reperfusion Cardioprotection (Strong Preclinical)
Evidence level: Multiple animal models
Beyond acute function improvement, hexarelin protects the heart from ischemia-reperfusion injury — the damage that occurs when blood flow is restored after a period of restriction (as in heart attack or surgery).
Hexarelin prevented increases in left ventricular end-diastolic pressure, reduced creatine kinase release (a marker of cardiac cell death), and enhanced recovery of contractility after ischemic events. These effects occurred in GH-deficient rats, confirming they are GH-independent (De Gennaro-Colonna et al., 1997).
The protective mechanism involves interleukin-1 signaling. Hexarelin activates IL-1-mediated prosurvival pathways in cardiomyocytes, reducing apoptosis during ischemia-reperfusion (Wang et al., 2017).
After experimental myocardial infarction, hexarelin treatment improved cardiac function compared to untreated controls (Locatelli et al., 1999).
4. Anti-Atherosclerotic Effects (Animal Evidence)
Evidence level: Animal studies
Hexarelin suppressed atherosclerosis in rats fed a high-lipid diet combined with vitamin D3 (a standard atherosclerosis induction protocol). Treated animals showed significantly reduced arterial plaque formation (Ma et al., 2009).
Chronic hexarelin administration also attenuated cardiac fibrosis in spontaneously hypertensive rats — a model of hypertensive heart disease (McDonald et al., 2012). This anti-fibrotic effect is potentially valuable for preventing the progressive cardiac remodeling that occurs with chronic hypertension.
These findings extend the CD36-mediated cardioprotection story beyond acute events into chronic disease prevention. The evidence is preclinical only — no human atherosclerosis or anti-fibrotic trials have been conducted.
5. Bone Mineral Content (Animal Evidence)
Evidence level: Animal studies
In adult female rats, both hexarelin and ipamorelin increased bone mineral content with chronic administration (Svensson et al., 2000). This is consistent with the known effects of GH/IGF-1 on bone metabolism — sustained GH elevation promotes osteoblast activity and bone mineralization.
Whether this translates to meaningful osteoporosis prevention or treatment in humans has not been tested. The effect is likely mediated by GH/IGF-1 rather than hexarelin-specific mechanisms, meaning other GHRPs may produce similar bone effects.
Ready to buy? Compare verified vendors on our best hexarelin sources page, or browse all coupon codes for up to 50% off.
